6月24日，Argenx SE夜盘上涨5.46%，报900.0美元/股，成交额5.13万美元。
消息面上，法国巴黎银行近日将Argenx评级为"跑赢大盘"，并给出1,219美元的目标价，较当前股价隐含较大上行空间。据FactSet数据，该股分析师平均评级为"买入"，平均目标价为1,064.53美元。法国巴黎银行的目标价明显高于市场共识，对市场情绪形成积极提振，推动股价延续近日涨势。
Argenx SE是一家处于商业阶段的全球性生物制药公司，专注开发用于治疗严重自身免疫性疾病的差异化疗法。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.